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Available online 17 December 2015Cognitive dysfunction is a common comorbidity in people with epilepsy, but its causes remain unclear. It may be
related to the etiology of the disorder, the consequences of seizures, or the effects of antiepileptic drug treatment.
Genetics may also play a contributory role. We investigated the influence of variants in the genes encoding
neuron-restrictive silencer factor (NRSF) and brain-derived neurotrophic factor (BDNF), proteins previously
associated with cognition and epilepsy, on cognitive function in people with newly diagnosed epilepsy. A total
of 82 patients who had previously undergone detailed neuropsychological assessmentwere genotyped for single
nucleotide polymorphisms (SNPs) across the NRSF and BDNF genes. Putatively functional SNPs were included in
a genetic association analysis with specific cognitive domains, includingmemory, psychomotor speed, and infor-
mation processing. Cross-sectional and longitudinal designs were used to explore genetic influences on baseline
cognition at diagnosis and change from baseline over the first year since diagnosis, respectively. We found a
statistically significant association between genotypic variation and memory function at both baseline (NRSF:
rs1105434, rs2227902 and BDNF: rs1491850, rs2030324, rs11030094) and in our longitudinal analysis (NRSF:
rs2227902 and BDNF: rs12273363). Psychomotor speed was also associated with genotype (NRSF rs3796529)
in the longitudinal assessment. In line with our previous work on general cognitive function in the healthy
aging population, we observed an additive interaction between risk alleles for the NRSF rs2227902 (G) and
BDNF rs6265 (A) polymorphismswhichwas again consistentwith a significantly greater decline in delayed recall
over thefirst year since diagnosis. These findings support a role for theNRSF–BDNF pathway in themodulation of
cognitive function in patients with newly diagnosed epilepsy.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Cognitive decline is a common and important comorbidity in people
with epilepsy and is well documented in those with long-standing in-
tractable seizures [1–5]. In contrast, comparatively few studies have ex-
plored the natural history of cognitive function in cohorts of patientsult Memory and Information
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. This is an open access article underwith newly diagnosed epilepsy [3,4,6–8]. One such study enrolled a
subgroup of participants from the UK-based Standard and New
Antiepileptic Drug (SANAD) trials [9,10] and assessed their long-term
cognitive outcomes using a neuropsychological test battery performed
at initial presentation (baseline) and again at 12months and an average
of 5 years thereafter. Individuals with new-onset epilepsy were sig-
nificantly impaired, in comparison to healthy controls, in cognitive
domains specifically relating tomemory, psychomotor speed, and infor-
mation processing both at baseline, using a cross-sectional design, and
over the first 5 years of treatment, using a longitudinal design [3,4]. A
number of studies support this finding, albeit with some inconsistencies
in the cognitive domains affected [11–18], but there are also contradic-
tory reports in the literature that suggest improvements or at least no
change in the cognitive function of people with epilepsy over time
[7,19–22]. These discrepancies are likely the result of differingmethod-
ologies applied across different research groups.
The exact cause of cognitive decline in people with epilepsy remains
unclear and may be reflective of multiple factors, including thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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seizures, the adverse effects of antiepileptic drug (AED) exposure, and
psychosocial dysfunction [1–5]. Antiepileptic drugs have been consid-
ered the principal culprits, with memory, attention, psychomotor
speed, and information processing being the cognitive domains most
commonly reported to be affected following drug treatment [23].
However, recent work suggesting that some people with epilepsy are
cognitively compromised from the time of initial diagnosis would advo-
cate the involvement of more intrinsic biological processes, including
epileptogenesis [4,24]. Genetics may also play a contributory role.
Polymorphic variants in genes encoding neuron-restrictive silencer
factor (NRSF) and brain-derived neurotrophic factor (BDNF) are known
to be correlated with cognitive ability in the elderly [25–28]. Neuron-
restrictive silencer factor, a transcriptional repressor reported to regulate
the expression of more than 2000 genes [29], and its downstream target
BDNF, a neuron-specific growth factor involved in neurogenesis, cell sur-
vival, and synaptic plasticity [30–33], have been shown to be differential-
ly regulated in rodent models of epilepsy [34–43]. The involvement of
these two genes in both cognition and epilepsy supports a role for the
NRSF–BDNF pathway in epilepsy-associated cognitive dysfunction.
Consistent with this pathway being modulated by drug action, several
AEDs modify NRSF signaling in neuroblastoma cells [44,45].
We have undertaken a study of variation in theNRSF and BDNF genes
and its association with cognitive function in individuals with newly di-
agnosed epilepsy andwith the change in cognitive function over the first
year of treatment following diagnosis. We used a haplotype-tagging ap-
proach to assess genetic variation and drew DNA samples and cognitive
data from the subgroup analysis of the SANAD trial [3,4].
2. Material and methods
2.1. Subjects
A total of 2437 patients were recruited into the SANAD trials (ISRCTN
38354748) [9,10], of whom 155 were included in the subgroup analysis
of cognitive function [3,4]. Of these, 84 patients had both baseline neuro-
psychological assessment and a DNA sample, with 70 also having further
neuropsychological assessment at approximately 12 months after initial
presentation. A comprehensive description of the patient population
is provided elsewhere [3,4,9,10]. All subjects were of self-reported
Caucasian ancestry and were neurologically normal, MRI negative, and
had not previously been treated with any AED. Collection of DNA was
approved by the North-West Multicentre Research Ethics Committee
in August 2002 (ref: MREC 02/8/45). All patients, or their parents/
guardians in the case of minors, provided written informed consent to
the use of their DNA and relevant clinical information in this analysis.
2.2. Cognitive assessment data
Patients recruited into the SANAD trial were assessed for cog-
nitive function at baseline and during follow-up studies using aTable 1
Selected cognitive tests employed in this analysis.
Analysis Domain Test
Cross-sectional Memory Figure recognition (serial task)
Rey Auditory Verbal Learning Task, AVLT
(immediate and delayed)
Story recall (immediate)
Psychomotor speed Finger tapping (dominant hand)
Adult Memory and Information Processing
(average speed)
Longitudinal Memory Rey Auditory Verbal Learning Task, AVLT
(immediate and delayed)
Psychomotor speed Visual reaction time, VRT (nondominant ha
Information processing Computerized Visual Search Task, CVST
Cognitive tests selected based on aspects of the battery previously shown to significantly differneuropsychological test battery designed to assess multiple cognitive
domains, including memory, psychomotor speed, information process-
ing,mentalflexibility, andmood. The test batterymethods are described
in detail elsewhere [4]. Only those aspects of the battery that had previ-
ously been shown to differ significantly between patients with epilepsy
and healthy controls were employed in the genetic association analysis
(see Table 1). All 84 subjects contributed to a cross-sectional analysis
of genetic influences on baseline cognitive function. The 70 patients
who also had a 12-month neuropsychological assessment were addi-
tionally included in a longitudinal analysis, investigating the influence
of genetic variants on the change in cognitive function from baseline.
2.3. Selection of genetic variants
Markers mapping to the NRSF and BDNF genes and their respective
flanking sequences (10 kb upstream and downstream) were selected
based on implications from the literature and/or maximum genetic
coverage through selection of haplotype-tagging SNPs (htSNPs).
Haplotype-tagging SNPs were identified using the pairwise-tagging
function (r2 threshold, 0.8) within Haploview 4.1 software (www.
broad.mit.edu/mpg/haploview/) and genotype data corresponding to
individuals from the CEPH trios of European descent from HapMap
Genome Browser release #28 (August 2010, NCBI build 36, dbSNP
b126). Single nucleotide polymorphisms were filtered to include only
those with a minor allele frequency (MAF) of greater than 5% within a
Caucasian population.
2.4. Genotyping
A total of 38 SNPs were selected for genotyping: 14 in NRSF and 24
in BDNF. Multiplex primer assays were designed using Sequenom
Assay Design software (https://mysequenom.com/default.aspx). Single
nucleotide polymorphisms were divided across two 20-plex assays.
Oligonucleotides were purchased from Metabion (Martinsried,
Germany). Polymerase chain reaction assays were carried out on a Veriti
thermal cycler (Applied Biosciences, Carlsbad, CA, USA) in a 384-wellmi-
crotiter plate using 20 ng of genomic DNA and with a final reaction vol-
ume of 4 μl. As a measure of quality control, six replication samples and
six blank controls were used. Genotyping was performed on a MALDI-
TOF-based Sequenom iPLEX MassARRAY® platform (Sequenom Inc.,
San Diego, CA, USA), according to the manufacturer's instructions.
2.5. Data analysis
Descriptive analysis of the patient cohort was carried out using SPSS
22.0 (see Table 2). Cognitive tests used for cross-sectional and longitudi-
nal analyses are listed in Table 1. A total of ten functional and/or
nonsynonymous SNPs were selected for the genetic association analysis
based on evidence from the literature (references listed in Table 3).
These included three SNPs in NRSF (rs1105434, rs2227902, rs3796529)
and seven SNPs in BDNF (rs1491850, rs12273363, rs2030324,Measured variable
Number of figures correctly identified in the serial task
Sum of words recalled over the 5 trials and the number of words recalled
following a 30-minute delay
Number of story units recalled immediately and following a 10-minute delay
Average number of taps for the dominant hand across five trials
Average number of digits crossed out over two trials
Sum of words recalled over the 5 trials and the number of words recalled
following a 30-minute delay
nd) Average reaction time (min/s) for the dominant and nondominant hand
Average speed of response (seconds)
between patients with epilepsy and healthy controls [4].
Table 2
Demographic and clinical profile of the study cohort at baseline and 12-month assessment.
Variable Baseline
(n = 82)
12 months
(n = 70)
Sex Males (n) 37 31
Females (n) 45 39
Age Mean [range] 40 [15–71] 42 [16–70]
Epilepsy type Generalized (n) 15 13
Focal (n) 67 57
No. of previous seizures at baseline Mean [range] 112 [2–3300] –
Remission status at follow-up Seizure-free (n) – 19
119A. Warburton et al. / Epilepsy & Behavior 54 (2016) 117–127rs11030108, rs6265, rs7124442, rs11030094). A schematic representa-
tion of the genomic coverage of these htSNPs is shown in Fig. 1. To deter-
mine associations between cognitive test scores and genotype frequency,
regression analysis and expectation–maximization optimization was
performed as it accounts for the estimated maximum likelihood of pa-
rameters for the longitudinal model [46]. Analysis was based on multi-
level mixed-effects linear regression using Restricted Maximum
Likelihood (REML) which maximizes the estimated likelihood of vari-
ance components affecting the observed measurement (i.e., cognitive
test score), invariant to the fixed effects [47]. The REML regression was
applied to correct for biases that may have arisen due to selection
[48,49]. To correct for multiple testing, the data were permutated
1000 times. Permutation testing was performed with respect to the
number of markers at the gene level. The REML regression and permuta-
tion testing were performed using Stata v.9.2. Cognitive data were
normally distributed, and age, sex, epilepsy type, number of previous sei-
zures at baseline (continuous variable, cross-sectional analysis), andTable 3
Minor allele frequencies and Hardy–Weinberg equilibrium of NRSF and BDNF SNPs.
Gene Marker Chromosomal
position
Base pair change
(majorNminor allele)
NRSF rs3806746 57773330 ANG
rs4109037 57775609 ANT
rs3755901 57775996 ANT
rs3000 57777945 CNT
rs1713985 57786450 ANC
rs13125082 57787000 TNG
rs6847086 57791864 GNA
rs1277306 57792078 TNC
rs1105434 57793751 GNA
rs2227902 57797100 GNT
rs3796529 57797414 GNA
rs2227901 57798189 GNA
rs781667 57798469 TNC
BDNF rs1491851 27752763 CNT
rs2049048 27750586 CNT
rs1491850 27749725 TNC
rs11030123 27748285 GNA
rs12273363 27744859 TNC
rs11030121 27736207 CNT
rs7934165 27731983 ANG
rs2030324 27726915 TNC
rs988748 27724745 CNG
rs2049046 27723775 ANT
rs7127507 27714884 TNC
rs7103411 27700125 TNC
rs11030108 27695464 GNA
rs2049045 27694241 GNC
rs11030104 27684517 ANG
rs11030102 27681596 CNG
rs6265 27679916 GNA
rs7124442 27677041 TNC
rs4923463 27672500 ANG
rs10501087 27670108 TNC
rs7927728 27667472 GNA
rs11602246 27660926 CNG
rs11030094 27659775 GNA
Markers in bold font represent the 10 SNPs selected for further analysis. Genotype distribution re
HWE, Hardy–Weinberg equilibrium; htSNPs, haplotype-tagging single nucleotide polymorphisfreedom from seizures since baseline (categorical variable, longitudinal
analysis) were accounted for by covarying their effects. All P-values
lower than 5% were regarded as significant. Linkage disequilibrium
(LD) analysis was performed using the D-prime (D′) statistic which
states the normalized covariance for a given pair of markers where a
D′ value of 1 represents complete LD. Composite genotype analysis was
performed using Golden HelixTree Genetic Analysis software version
5.0 (Golden Helix, Inc., Bozeman, MT, USA).
3. Results
3.1. Demographic and clinical characteristics
A summary of the study population is provided in Table 2. Themean
age of subjects at baseline was 40 years, with a range of 15 to 71 years.
Thereweremarginallymore females (55%), and themajority of subjects
were considered to have focal epilepsy (82%). Themean number of days
from baseline assessment to the 12-month follow-up assessment was
388 days, ranging from 350 to 566 days. The number of individuals
that were seizure-free for the entire period from baseline until the
12-month assessment was 19.
3.2. Association of NRSF and BDNF SNPs with memory related tasks
A total of 36 SNPs were successfully genotyped; these are listed in
Table 3. All were in Hardy–Weinberg equilibrium (HWE) and had a
MAF N 0.05. Two SNPs (NRSF rs11736869 and BDNF rs11030119)
from the original panel were excluded as they had a call rate of less
than 95%, the accepted cut-off for genotype-based studies [50]. TwoGenotype
distribution
HWE
P-value
MAF Reference
25/40/6 0.07 0.37
65/17/0 0.30 0.10
64/17/1 0.91 0.12
27/36/9 0.57 0.38
68/14/0 0.40 0.09
38/27/6 0.70 0.28
25/36/9 0.48 0.39
35/40/7 0.34 0.33
29/33/9 0.93 0.36 [51]
57/15/0 0.32 0.10 [25]
49/26/2 0.50 0.20 [25,52]
54/26/2 0.58 0.18
40/38/4 0.18 0.28
33/27/12 0.13 0.35
47/18/4 0.22 0.19
24/44/14 0.42 0.44 [26,53–55]
65/14/2 0.24 0.11
45/27/0 0.05 0.19 [53,55–58]
34/28/9 0.40 0.32
16/35/14 0.53 0.49
25/37/16 0.73 0.44 [27,57,71]
50/28/3 0.70 0.21
28/35/18 0.27 0.44
34/27/11 0.16 0.34
43/27/2 0.35 0.22
38/31/11 0.26 0.33 [26]
55/25/2 0.67 0.18
51/28/3 0.72 0.21
43/34/3 0.23 0.25
53/27/2 0.50 0.19 [25,27,59–66]
38/31/13 0.13 0.35 [59]
52/27/3 0.83 0.20
44/26/2 0.42 0.21
60/8/1 0.25 0.07
63/9/0 0.57 0.06
28/33/11 0.80 0.38 [26,67]
presents AA/Aa/aa,where ‘A’ is thewild type allele and ‘a’ the variant allele. Abbreviations:
ms; MAF, minor allele frequency.
Fig. 1. Schematic representation of genotyped haplotype-tagging SNPs (htSNPs) spanning the BDNF (top) and NRSF (bottom) genes. Highlightedmarkers represent those selected for ge-
notype analysis; dark gray indicates htSNPs and/or functional SNPs selected for inclusion in the genetic association, and light gray indicates SNPs captured by these selected htSNPs
(r2 N 0.88) from linkage disequilibrium (LD) analysis of the genotype data. The remaining SNPs represent genetic coverage over the entire locus, including 10 kb flanking sequence, as
determined by pairwise-tagging (r2 N 0.8, indicating that a pair of SNPs are in strong LD and that one allele at one locus tags another allele at separate locus meaning that only one SNP
needs to be genotyped) using HapMap CEU genotype data and Haploview 4.1 software (www.broad.mit.edu/mpg/haploview/). *SNPs shown from genetic analysis to be significantly
associated. Image generated using UCSC Genome browser (https://genome.ucsc.edu/).
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control checks. Ten SNPswere selected for inclusion in the genetic asso-
ciation analysis on the basis of maximum genetic coverage through the
use of htSNPs (Fig. 1) or based on known or proposed functional effects
(see Reference, Table 3) [25–27,51–68]. These included three SNPs in
NRSF (rs1105434, rs2227902, rs3796529) and seven SNPs in BDNF
(rs1491850, rs12273363, rs2030324, rs11030108, rs6265, rs7124442,
rs11030094).
Regression analysis of cross-sectional cognitive test scoreswith indi-
vidual SNP genotypes indicated statistically significant associations for
the respective NRSF markers rs1105434 (P = 0.03) and rs2227902
(P = 0.02) with delayed recall, as assessed by the Rey Auditory Verbal
Learning Task (AVLT), and serial recall, as assessed by the figure recog-
nition task (Table 4). Three BDNFmarkers were also associatedwith the
Rey AVLT in the cross-sectional analysis: rs1491850 (P= 0.05, immedi-
ate recall), rs11030094 (P = 0.02, delayed recall), and rs2030324
(P = 0.03, immediate recall and P = 0.01, delayed recall) (Table 4). In
the longitudinal analysis, a mixed effect REML regression model was
used to account for repeated measures and within-subject covariance
[47–49]. After correcting for covariate effects, NRSF rs2227902 was
again identified as being significantly (P= 0.01) associated with mem-
ory function aswas BDNF rs12273363 (P=0.03) and both in relation to
Rey AVLT delayed recall scores. The independent effect of these SNPs in
predicting memory function showed only BDNF rs12273363 to be sig-
nificant (P = 0.04) (Table 5). Psychomotor speed was also found to be
significantly affected by genotype (NRSF rs3796529, P = 0.04) in thelongitudinal analysis, assessed through visual reaction time (nondomi-
nant hand, Table 5). In both the cross-sectional and longitudinal analy-
ses, no significant associations were found between individual SNP
genotypes and cognitive test scores measuring information processing
(Tables 4 and 5).
3.3. Haplotype structure of NRSF and BDNF genes
To ensure that the markers identified from our genetic association
were reflective of genetic differences associated with cognitive perfor-
mance as opposed to differences in ancestry, LD analysis was performed
using Lewontin's normalized D′ statistic [69] and compared to LD pat-
terns generated using genotype data from the HapMap CEU cohort as
a reference group (Figs. 2 and 3). Haplotype blocks were defined using
95% confidence intervals proposed by Gabriel et al. [70]. Using this
method, markers within the BDNF gene were shown to be inherited
as a single haplotype block spanning 76 kb,with evidence of recombina-
tion within the promoter sequence represented by low D′ values
(Fig. 2). Within the NRSF gene, a single haplotype block spanning
774 bp was defined, composed of the rs3796529 and rs2227901
markers (Fig. 3A). Analysis of the genetic coverage over the locus cap-
tured by htSNPs selected for inclusion in our genetic association study
using genotype data from the HapMap CEU cohort showed an addition-
al haplotype block of strong LD spanning 21 kb (Fig. 3B). Evidence of re-
combination, depicted by white regions on the LD plot, was observed in
the region containing a coding variable number tandem repeat (VNTR)
Table 4
Genetic association analysis of cross-sectional cognitive data using a regression model adjusted for age, sex, epilepsy type, and number of previous seizures at baseline.
Gene SNP Cognitive test β Adjusted
P-valuea
95% CI
Lower Upper
NRSF rs1105434 Finger tapping (dominant hand) −0.98 0.61 −4.53 2.57
Story recall (immediate) 0.64 0.22 −0.43 1.71
Figure recognition (serial) 1.31 0.07 −0.22 2.83
Rey AVLT (immediate) 1.78 0.23 −1.27 4.82
Rey AVLT (delayed) 1.00 0.03⁎ 0.04 2.00
AMIPB average speed −3.57 0.06 −7.37 0.24
rs2227902 Finger tapping (dominant hand) −1.78 0.52 −7.63 4.06
Story recall (immediate) 0.26 0.74 −1.48 2.00
Figure recognition (serial) −2.63 0.02⁎ −5.06 −0.19
Rey AVLT (immediate) 1.52 0.55 −3.42 6.46
Rey AVLT (delayed) 0.20 0.83 −1.80 1.41
AMIPB average speed −0.93 0.76 −7.16 5.31
rs3796529 Finger tapping (dominant hand) 1.19 0.58 −2.90 5.28
Story recall (immediate) −0.50 0.42 −1.69 0.69
Figure recognition (serial) 0.85 0.36 −0.93 2.62
Rey AVLT (immediate) −1.20 0.49 −4.73 2.34
Rey AVLT (delayed) −0.48 0.40 −1.63 0.68
AMIPB average speed 0.73 0.78 −3.86 5.32
BDNF rs1491850 Finger tapping (dominant hand) −1.76 0.28 −5.06 1.53
Story recall (immediate) 0.44 0.37 −0.51 1.38
Figure recognition (serial) 0.71 0.28 −0.66 2.08
Rey AVLT (immediate) 2.81 0.05⁎ 0.11 5.51
Rey AVLT (delayed) 0.56 0.20 −0.32 1.44
AMIPB average speed −2.78 0.12 −6.30 0.73
rs12273363 Finger tapping (dominant hand) −3.96 0.12 −8.69 −0.76
Story recall (immediate) 0.82 0.25 −0.62 2.25
Figure recognition (serial) 0.21 0.84 −1.88 2.30
Rey AVLT (immediate) 2.62 0.20 −1.46 6.71
Rey AVLT (delayed) 0.55 0.42 −0.78 1.88
AMIPB average speed −1.32 0.60 −6.53 3.90
rs2030324 Finger tapping (dominant hand) 0.33 0.85 −2.87 3.53
Story recall (immediate) −0.50 0.29 −1.42 0.43
Figure recognition (serial) −1.08 0.09 −2.35 0.19
Rey AVLT (immediate) −2.78 0.03⁎ −5.43 −0.13
Rey AVLT (delayed) −1.19 0.01⁎ −2.01 −0.36
AMIPB average speed 0.96 0.60 −2.54 4.46
rs11030108 Finger tapping (dominant hand) −1.49 0.34 −4.68 1.70
Story recall (immediate) 0.59 0.19 −0.30 1.47
Figure recognition (serial) 0.61 0.34 −0.69 1.90
Rey AVLT (immediate) 2.57 0.06 −0.02 5.17
Rey AVLT (delayed) 0.74 0.09 −0.10 1.57
AMIPB average speed 1.10 0.53 −2.26 4.47
rs6265 Finger tapping (dominant hand) 0.91 0.67 −3.19 5.00
Story recall (immediate) −0.31 0.61 −1.49 0.88
Figure recognition (serial) 0.32 0.71 −1.37 2.01
Rey AVLT (immediate) 0.89 0.60 −2.56 4.35
Rey AVLT (delayed) 0.33 0.58 −0.78 1.43
AMIPB average speed −1.14 0.07 −8.48 0.20
rs7124442 Finger tapping (dominant hand) −1.62 0.29 −4.65 1.40
Story recall (immediate) 0.44 0.33 −0.43 1.30
Figure recognition (serial) 0.45 0.48 −0.80 1.69
Rey AVLT (immediate) 2.34 0.06 −0.13 4.81
Rey AVLT (delayed) 0.69 0.08 −0.11 1.48
AMIPB average speed 1.02 0.53 −2.19 4.23
rs11030094 Finger tapping (dominant hand) 2.57 0.16 −0.87 6.00
Story recall (immediate) −0.36 0.48 −1.42 0.69
Figure recognition (serial) −1.30 0.07 −2.79 0.20
Rey AVLT (immediate) −2.79 0.05 −5.73 0.15
Rey AVLT (delayed) −1.01 0.02⁎ −2.02 −0.13
AMIPB average speed 2.62 0.15 −1.21 6.47
Negative β values indicate lower test scores for each copy of the minor allele. Abbreviations: AMIPB, Adult Memory and Information Processing Battery; AVLT, Auditory Verbal Learning
Task; β, beta coefficient; CI, confidence interval.
a Permutation testing for the number of markers at the gene level.
⁎ P ≤ 0.05.
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(Fig. 3B), shown from our genetic association to be significantly
correlatedwithmemory performance in patients with newly diagnosed
epilepsy (Tables 4 and 5).
Pairwise tagging SNP analysis (r2 N 0.8) of genotype data re-
vealed that NRSF rs1105434, rs2227902, and rs3796529 were
in strong LD with the rs3000 (r2 = 0.94), rs3755901 (r2 = 1.0),and rs2227901 (r2 = 1.0) markers, respectively. For BDNF, the
markers rs1491850, rs12273363, rs2030324, rs11030108, rs6265,
rs7124442, and rs11030094 represented 13/24 SNPs genotyped
for this gene (see Fig. 1 for alleles captured), indicating strong LD
across the gene. Linkage disequilibrium patterns across the BDNF
and NRSF genes in this modest sample showed no major differences
in comparison to LD-plots generated from the HapMap CEU dataset
Table 5
Genetic association analysis of longitudinal cognitive data using a mixed-effect REML regression model adjusted for age, sex, epilepsy type, and remission status at 12-month follow-up
(seizure-free or not).
Gene SNP Cognitive test β P-value Adjusted
P-valuea
95% CI
Lower Upper
NRSF rs1105434 VRT (nondominant hand)b 0.06 0.64 0.70 −0.21 0.34
CVSTb −0.01 0.95 0.85 −0.36 0.34
Rey AVLT (immediate) 0.52 0.91 0.90 −8.20 9.25
Rey AVLT (delayed) 0.12 0.94 0.74 −2.74 2.98
rs2227902 VRT (nondominant hand)b −0.07 0.68 0.96 −0.43 0.28
CVSTb 0.04 0.84 0.89 −0.42 0.52
Rey AVLT (immediate) −6.68 0.23 0.08 −17.50 4.14
Rey AVLT (delayed) 3.53 0.08 0.02⁎ −7.49 0.42
rs3796529 VRT (nondominant hand)b 0.36 0.04⁎ 0.08 0.02 0.71
CVSTb −0.25 0.29 0.29 −0.71 0.21
Rey AVLT (immediate) 2.23 0.68 0.38 −8.30 12.77
Rey AVLT (delayed) −1.29 0.53 0.94 −5.28 2.69
BDNF rs1491850 VRT (nondominant hand)b 0.15 0.26 0.43 −0.11 0.40
CVSTb 0.17 0.27 0.73 −0.14 0.48
Rey AVLT (immediate) −2.33 0.58 0.43 −10.52 5.86
Rey AVLT (delayed) −1.81 0.19 0.08 −4.55 0.92
rs12273363 VRT (nondominant hand)b 0.09 0.59 0.69 −0.23 0.41
CVSTb 0.25 0.24 0.45 −0.16 0.65
Rey AVLT (immediate) −8.15 0.12 0.07 −18.28 1.97
Rey AVLT (delayed) −3.99 0.04⁎ 0.01⁎ −7.74 −0.25
rs2030324 VRT (nondominant hand)b 0.08 0.52 0.31 −0.17 0.34
CVSTb −0.13 0.39 0.36 −0.45 0.18
Rey AVLT (immediate) −3.80 0.32 0.43 −11.35 3.75
Rey AVLT (delayed) −1.10 0.43 0.84 −3.80 1.60
rs11030108 VRT (nondominant hand)b 0.05 0.44 0.88 −0.18 0.28
CVSTb −0.00 0.98 0.90 −0.30 0.29
Rey AVLT (immediate) −0.73 0.83 0.51 −7.35 5.89
Rey AVLT (delayed) −0.58 0.66 0.33 −3.12 1.97
rs6265 VRT (nondominant hand)b 0.06 0.69 0.97 −0.23 0.35
CVSTb −0.02 0.93 0.53 −0.39 0.36
Rey AVLT (immediate) 1.03 0.84 0.64 −8.77 10.82
Rey AVLT (delayed) −0.46 0.81 0.86 −4.08 3.16
rs7124442 VRT (nondominant hand)b 0.08 0.48 0.61 −0.14 0.30
CVSTb −0.02 0.92 0.88 −0.29 0.26
Rey AVLT (immediate) −1.39 0.71 0.46 −8.62 5.84
Rey AVLT (delayed) −0.37 0.78 0.48 −3.01 2.26
rs11030094 VRT (nondominant hand)b 0.21 0.13 0.05 −0.06 0.48
CVSTb −0.09 0.61 0.69 −0.45 0.27
Rey AVLT (immediate) −6.44 0.18 0.19 −15.76 2.87
Rey AVLT (delayed) −1.86 0.24 0.47 −4.95 1.22
Negative β values indicate lower test scores for each copy of theminor allele. AVLT, Auditory Verbal Learning Task; β, beta coefficient; CI, confidence interval; CVST, Computerized Visual
Search Task; REML, Restricted Maximum Likelihood; VRT, visual reaction time.
a Corrected for significant covariate effects (age).
b Analysis undertaken on log-transformed data.
⁎ P b 0.05.
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tion in our model.
3.4. Association of NRSF–BDNF composite genetic model with Rey AVLT
(delayed) scores
We have previously shown that the major allele of NRSF rs2227902
(G) is associated with reduced cognitive performance in the elderly
[25]. To determine its effect on cognition in adults with newly diag-
nosed epilepsy, we correlated the number of rs2227902 risk alleles
with delayed recall Rey AVLT scores as these were shown to be signifi-
cantly associated in our longitudinal analysis (P = 0.02, Table 5).
Fig. 4A illustrates a similar trend to that observed in the aging popula-
tion, with individuals homozygous for the wild type (WT) allele deteri-
orating to a significantly (P= 0.04, unpaired t-test) greater extent than
individuals possessing at least one copy of the minor allele in terms of
delayed recall in Rey AVLT.
Interaction between the rs2227902 marker and the BDNF rs6265
marker has been described previously [25]. A composite-genotype
model was used in order to determine association between the cross-
sectional and longitudinal cognitive test scores with the sum of risk al-
leles for the rs2227902 and rs6265 markers. The WT allele (G), whichtags a 5-copy coding VNTRwithin exon 4 of the NRSF gene, was consid-
ered to be the risk allele for rs2227902, whereas the minor allele
(Met66-A) was considered the risk allele for rs6265 [25,27]. Additive-
effect linear regression analysis with permutation testing showed that
the change in delayed recall in Rey AVLT in the longitudinal analysis
was significantly associated with the number of risk alleles (P
value = 0.02; Fig. 4B). In our previous report, this interaction was
shown to specifically reflect a haplotype containing the rs2227902
(T) marker, which tags a 4-copy variant of the NRSF VNTR, and BDNF
rs6265 (Val66-G) [25]. Individuals possessing this haplotype had signif-
icantly higher scores of general intelligence than those with one or nei-
ther of these variants, or in individuals possessing the NRSF–BDNF ‘risk’
variants. To test the direction of this interaction in terms of risk or
nonrisk alleles predicting cognitive performance, linear regression was
applied to the different allele groupings as shown in Table 6. Due to
the low minor allele frequencies of rs2227902 and rs6265, individuals
were grouped by the presence or absence of the minor alleles. Data
were controlled for age, sex, and epilepsy type by covarying their effects.
Consistent with an additive interaction between the rs2227902 and
rs6265 ‘nonrisk’ alleles in determining higher cognitive performance
in the elderly, our composite genotype model showed a positive corre-
lation between the presence of the rs2227902 (T)_rs6265 (G) genotype
Fig. 2. Linkage disequilibrium (LD) and haplotype analysis of BDNF markers in patients with newly diagnosed epilepsy. Haplotype block structure of the BDNF gene indicating strong LD
(dark gray squares) based on D′ estimates calculated from 82 individuals with newly diagnosed epilepsy. Haplotype blocks, represented by a black triangular border, were determined
using 95% confidence intervals proposed by Gabriel et al. [70] which defined a single block for the BDNF gene. Individual haplotypes making up the BDNF haplotype block are depicted
above the LD plot and are compared to haplotype frequencies present in the HapMap CEU cohort. Haplotypes with a minor allele frequency of 0.05 or above were included. Haplotype
structure did not significantly differ between the two cohorts (P = 0.74, chi-square test; χ2). LOD; log of the likelihood odds ratio, a measure of confidence in the D′ value.
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beta-coefficient 0.31). No such interaction was observed between the
other NRSF–BDNF groupings and cognitive test scores which again sup-
ports previous findings [25].
4. Discussion
Cognitive dysfunction has been reported in people with newly diag-
nosed epilepsy. These individuals are naïve to the long-term effects of
AED treatment and the cumulative effects of recurrent seizures, sug-
gesting the involvement of other intrinsic and/or environmental factors.
In this study, we provide preliminary evidence to suggest that variants
within the NRSF and BDNF genes influence cognitive function in adults
with newly diagnosed epilepsy at both baseline and over the first year
after diagnosis. Genetic effects were specific to memory-related tasks
and psychomotor speed (longitudinal analysis). In the cross-sectional
analysis, we found significant associations for NRSF rs1105434 and
rs2227902 and BDNF rs1491850, rs2030324, and rs11030094, with
NRSF rs2227902 and rs3796529 and BDNF rs12273363 implicated in
the longitudinal model. These findings are consistent with previousstudies showing association between the NRSF and BDNF genes and
cognitive function in a healthy aging population and in neurological
disorders [58,71,72].
All of the SNPs identified in this study have previously been associat-
edwith neurological disease or asmarkers of phenotypic traits associat-
ed with CNS dysfunction. For example, the BDNF SNPs rs1491850 and
rs11030094, shown in our cross-sectional analysis to be associated
with immediate and delayed recall in the Rey AVLT, respectively, have
recently been identified as important genetic variants in Alzheimer's
disease-related neurodegeneration and cognitive impairments [26,67].
The BDNF rs1491850 has also been implicated in treatment response
phenotypes and remission status in major depressive disorder [54,55].
We also observed an association between Rey AVLT scores and the
BDNF SNP rs2030324 which has previously been associated with cogni-
tive processes in healthy aging [27] and multiple sclerosis [73].
Significant associations with delayed recall performance were also
apparent in our longitudinal analysis with respect to NRSF rs2227902
and BDNF rs12273363. This may reflect a distinct regulatory pathway
in themodulation of verbal memory in late-onset epilepsy. The location
of five of the seven associated SNPs within noncoding regions of the
Fig. 3. Linkage disequilibrium (LD) and haplotype analysis of NRSFmarkers in patients with newly diagnosed epilepsy. A, Haplotype block structure of the NRSF gene in the SANAD cohort
(top) and the HapMap CEU cohort (bottom) based on D′ (left) and r2 (right) estimates. A similar pattern of LD was observed between the two study cohorts. B, LD analysis in the HapMap
CEU cohort using alleles captured through haplotype-tagging indicates two haplotype blocks, represented by black triangular borders, and strong LD over the region. Haplotype blocks
were determined using 95% confidence intervals proposed by Gabriel et al. [70].
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enrichment of disease-associated SNPs within tissue-specific enhancers
[74–78]. Polymorphisms within such regulatory elements can altertranscription factor binding motifs and thus the expression of a gene
through modulation of signal transduction responses in both a tissue-
specific and stimulus-dependent manner. Dysregulation of the BDNF
Fig. 4. Association of NRSF–BDNF composite-genotype with Rey Auditory Verbal Learning
Task (AVLT) delayed recall scores over time. A, Association of NRSF rs2227902 with Rey
AVLT delayed recall scores. Group 1 represents individuals homozygous for the wild
type risk allele rs2227902 (G); Group 2 represents individuals possessing at least 1 copy
of the minor nonrisk allele rs2227902 (T). Horizontal lines represent the mean change
with standard deviation from baseline to 12-month reassessment scores. A lower score
correlates with a greater reduction in memory performance. A significant decrease in
test scores was observed between the two groups (Mann–Whitney test, P = 0.014).
B, Risk alleles for NRSF rs2227902 and BDNF rs6265 were grouped and the number of
alleles scored as follows: Group 1 represents 0–1 risk alleles, Group 2 represents 2 risk
alleles in individuals that were either heterozygous for each SNP or homozygous for
rs2227902 (G) and Group 3 represents 3–4 risk alleles. Linear regression analysis showed
a significant difference between the groups (P = 0.02).
Table 6
Association of NRSF–BDNF composite-genotype with Rey Auditory Verbal Learning Task
(AVLT) delayed recall scores over time.
NRSF–BDNF haplotype N Frequency β P-valuea
rs2227902 (G)_rs6265 (G) 35 50.0 −0.12 0.31
rs2227902 (G)_rs6265 (A) 18 25.7 −0.13 0.30
rs2227902 (T)_rs6265 (G) 12 17.1 0.31 0.01⁎
rs2227902 (T)_rs6265 (A) 5 7.1 −0.01 0.97
Major allele of NRSF, rs2227902 (G), and minor allele of BDNF, rs6265 (A), were consid-
ered risk alleles. Negative β scores indicate that the presence of risk alleles (or absence
of nonrisk alleles) correlates with lower test scores. Positive β scores indicate that the
presence of nonrisk alleles (or absence of risk alleles) correlates with higher test scores.
Abbreviations: AVLT, Auditory Verbal Learning Task; β, beta coefficient.
a Linear regressionmodel for association between the NRSFmarker rs2227902 and the
BDNF marker rs6265 with Rey AVLT delayed recall scores over time.
⁎ P b 0.05.
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Elaborate modulation of BDNF mRNA expression is mediated by nine
functional promoters, some of which are influenced by cis-regulatory
elements [58,83]. One such element, BE5.2, which contains the noncod-
ing SNP rs12273363, implicated inmemory performance in our longitu-
dinal assessment, has been shown to differentially regulate BDNF
promoter 4 activity in a stimulus-inducible, allele-specific, and tissue-
dependent manner [58]. This correlates with previous findings of
allele-specific differences in pro-BDNF density in postmortem brain tis-
sue in which the minor allele of rs12273363 was associated withreduced hippocampal expression [56]. Association between NRSF
rs3796529 and psychomotor speed was also found in our longitudinal
study; however, this did not withstand correcting for covariate effects.
The BDNF SNP rs6265 has been extensively studied in the field of
cognition, with many publications supporting its role in the regulation
of cognitive function. Our study did not find a direct association
between rs6265 and cognitive function in patients with epilepsy. How-
ever, when we analyzed this SNP in combination with NRSF rs2227902
based on our previous finding of an additive interaction between these
two polymorphisms in age-related cognitive function [25], the number
of risk alleles was inversely correlated with memory performance
(Fig. 4A).
Linear regression analysis of the different groupings of these two
SNPs based on the presence or absence of the risk or nonrisk alleles
showed that the genetic association was significant in relation to a
haplotype containing the nonrisk alleles NRSF rs2227902 (T) and
BDNF rs6265 (Val66-G), which correlated with higher Rey AVLT test
scores as indicated by the positive beta coefficient value (Table 6).
This is consistentwith previousfindings in the elderly cohort suggesting
that this allelic combination may improve cognitive performance or
slow the rate of cognitive decay over individuals possessing the pro-
posed risk variants which may predict risk for more rapid cognitive de-
cline over time, as demonstrated in BDNF rs6265 (Met66-A) carriers
relative to rs6265 (Val66-G) homozygotes in Alzheimer's disease [84].
Support for the NRSF–BDNF pathway as a potential mechanism in
cognitive dysfunction associated with neurological disorders comes
from studies on Huntington's disease, where it has been shown that
WT but not mutant huntingtin protein regulates BDNF transcription
through cytoplasmic sequestering of NRSF [85]. Furthermore, genetic
variants of the REST-interacting LIM domain protein (RILP/Prickle-1),
an important candidate involved in the nuclear translocation and
repressive functioning of NRSF [86], have been associated with
autosomal-recessive progressive myoclonus epilepsy–ataxia syndrome,
the symptoms of which include seizures and cognitive decline [87].
Epigenetic parametersmay also be important in this regulatory network
as suggested by interaction of the NRSF-silencing complex with the
histone demethylase SMCX, a gene implicated in X-linkedmental retar-
dation and epilepsy [88], resulting in chromatin remodeling and down-
stream regulation of NRSF target genes including BDNF. Other
chromatin remodeling proteins associated with this silencing complex
have been implicated in memory impairment, including histone
deacetylase 2 (HDAC2) [89,90] and methyl CpG binding protein 2
(MeCP2) which is mutated in Rett syndrome resulting in NRSF/
coREST-mediated repression of BDNF expression [91]. Further support
comes from evidence that glycolytic inhibitor 2-deoxy-D-glucose mod-
ulation of the NRSF–CBP (C-terminal binding protein) complex en-
hances the repressive chromatin environment surrounding the BDNF
gene, consequently blocking epileptogenesis [37,40]. In addition,
investigations into functional abnormalities observed in patients with
Korsakoff's syndrome, a neurological disorder caused by thiamine
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delayed memory performance [92]. Both NRSF and BDNF have been
linked to impairments of neurogenesis in this disorder [93]. Collectively
these studies support a role for dysregulation of the NRSF–BDNF path-
way in cognitive decline associated with neurological disease.
5. Conclusion
Our data support a trend towards association of polymorphic
variants within the NRSF and BDNF genes and memory-related tasks
in patients with a new diagnosis of epilepsy. These associations reached
statistical significance in both the cross-sectional and longitudinal
assessment suggesting the influence of genetic background on the
susceptibility to memory decline in adults with new onset epilepsy.
Our findings are consistent with previous literature in the field but
should be considered with caution, not least because of the small sam-
ple size. In addition, we were unable to account for potentially con-
founding variables including the influence of AED exposure or possible
practice effects associated with repeat application of cognitive tests.
Although they require replication in a larger study sample, these obser-
vations lend weight to the known involvement of NRSF–BDNF markers
in themodulation of cognitive performance in healthy aging and also in
neurological and psychiatric disorders.
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